Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.
about
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesHepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action.Interferon monotherapy in chronic hepatitis B.Low dose interferon alfa-2b for chronic hepatitis B in Asian countriesHepatitis C: virology, epidemiology, clinical course, and treatment.Management of chronic hepatitis B: consensus guidelinesComparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.HIV/hepatitis B virus co-infection: current challenges and new strategies.Hepatitis B virus polymerase impairs interferon-α-induced STA T activation through inhibition of importin-α5 and protein kinase C-δ.IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.Comparison of antiviral activity of recombinant and natural interferons against crimean-congo hemorrhagic Fever virus.Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.European guideline for the management of hepatitis B and C virus infections.Interferon: current and future clinical uses in infectious disease practice.Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.Statistical models for predicting a beneficial response to interferon-alpha in patients with chronic hepatitis B.Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.Hepatitis B: Prognosis and Treatment
P2860
Q27000080-FBA6809B-8EDC-47E0-A169-BD41EABD0317Q33687074-7C64914A-F6F8-4F95-A59F-CF9811769DBDQ33988044-63CAFA6B-34E3-49E8-BEF4-5CBA3F573654Q34375785-50F45E72-85B1-41A4-AA48-492434F5F00FQ35233238-C6651E5E-D7CE-4212-A811-3169A6595A07Q36849343-2A9F1289-02F9-4B51-95A9-CC3EEFD41664Q37149701-BDEB3103-CA6F-4145-A758-FC37B26D5453Q37630062-6C8863D7-8CFA-4CCE-A618-1D549AED22ACQ39274712-8C25000D-08A6-4430-B1D1-92A88D2E8AACQ39488926-852414FC-76F6-45CB-A883-3E297006A2CEQ40357292-562FBA1C-E47D-47F9-AED9-31F8D3F11405Q42980105-BB256763-183F-4611-A65C-73F0617CF950Q44084685-3007249E-C33C-4455-8810-CFFA076A3636Q44118049-298703D8-14C2-4B61-B867-80D6078985A0Q44717382-F6A2BF11-5DC8-4F95-A46D-98584DB41943Q45752264-7349F8A2-D661-4FDD-8464-F6E4E07A77A5Q50891579-0A434D39-7660-4718-B9D9-59B53A90F08FQ53385661-176C150F-91E9-4C8B-98C9-53304B56FB54Q58803261-4C2692A1-5ACF-4FA8-AB61-0C6F7CACA892
P2860
Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Randomised controlled trial of ...... ctors that influence response.
@en
Randomised controlled trial of interferon alfa 2A
@nl
type
label
Randomised controlled trial of ...... ctors that influence response.
@en
Randomised controlled trial of interferon alfa 2A
@nl
prefLabel
Randomised controlled trial of ...... ctors that influence response.
@en
Randomised controlled trial of interferon alfa 2A
@nl
P2093
P2860
P356
P1433
P1476
Randomised controlled trial of ...... ctors that influence response.
@en
P2093
H C Thomas
J A McDonald
J R Harris
P Karayiannis
P2860
P304
P356
10.1136/GUT.30.8.1116
P407
P577
1989-08-01T00:00:00Z